Infectious Diseases in Critical Care Medicine

25. Fowler VG Jr, Olsen MK, Corey GR, et al. Clinical identifiers of complicatedStaphylococcus aureus
    bacteremia. Arch Intern Med 2003; 163:2066–2072.


26. Espersen F, Frimodt-Moller N.Staphylococcus aureusendocarditis: a review of 119 cases. Arch Intern
    Med 1986; 146:1118–1121.


27. Kaech C, Elzi L, Sendi P, et al. Course and outcome ofStaphylococcus aureusbacteriemia: a
    retrospective analysis of 308 episodes in a Swiss tertiary-care centre. Clin Microbiol Infect 2006;
    12:345–352.


28. Chang, FY, MacDonald BB, Peacock JE, et al. A prospective multicenter study ofStaphylococcus aureus
    bacteremia. Incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin
    resistance. Medicine 2003; 82:322–332.


29. Bayer AS, Lam K, Ginzton L, et al.Staphylococcus aureusbacteremia: clinical, serological and
    echocardiographic findings in patients with and without endocarditis. Arch Intern Med 1987; 147:
    457–462.


30. Mirimanoff RO, Glauser MP. Endocarditis duringStaphylococcus aureussepticemia in a population of
    non-drug addicts. Arch Intern Med 1982; 142:1311–1313.


31. Mayhall CG. Diagnosis and management of infections of implantable devices used for prolonged
    venous access. Curr Clin Top Infect Dis 1992; 12:83–110.


32. Cunha BA. Clinical usefulness of highly elevated teichoic acid antibody (TAA) titers. Infect Dis Pract
    2005; 29:378–380.


33. Raad II, Sabbagh MF. Optimal duration of therapy for catheter-relatedStaphylococcus aureus
    bacteremia: a study of 55 cases and review. Clin Infect Dis 1992; 14:75–82.


34. Rosen AB, Fowler VG Jr, Corey GR, et al. Cost-effectiveness of transesophageal echocardiography to
    determine the duration of therapy for intravascular catheter-associatedStaphylococcus aureus
    bacteremia. Ann Intern Med 1999; 130:810–820.


35. Smits H, Freedman LR. Prolonged venous catheterization as a cause of sepsis. N. Engl J Med. 1967;
    276:1229–1233.


36. Mylotte JM, McDermott C. Staphylococcus aureus bacteremia caused by infected intravenous
    catheters. Am J Infect Control. 1987;15:1–6.


37. Sacks-Berg A, Strampfer MJ, Cunha BA. Intravenous line sepsis due to suppurative thrombophlebitis.
    Heart Lung 1987; 16:318–320.


38. Mylotte JM, McDermott C, Spooner JA. Prospective study of 114 consecutive episodes of
    Staphylococcus aureus bacteremia. Rev Infect Dis. 1987; 9:891–907.


39. Brusch JL. Infective Endocarditis. New York: Informa Healthcare; 2007.


40. Cunha BA. PersistentS. aureusBacteremia: a clinical approach. Infect Dis Prac 2005; 29:444–446.


41. Cunha BA. Antibiotic Essentials. 8th ed. Sudbury, MA: Jones & Bartlett; 2009.


42. Kucers A, Crowe SM, Grayson ML, et al. The use of antibiotics: a clinical review of antibacterial,
    antifungal and antiviral drugs. 5th ed. Oxford, UK: Butterworth-Heinemann; 1997.


43. Cunha BA. Oral antibiotic therapy of serious systemic infections. Med Clin North Am 2006; 90:
    1197–2222.


44. Gentry CA, Rodvold KA, Novack RM, et al. Retrospective evaluation of therapies forStaphylococcus
    aureusendocarditis. Pharmacotherapy 1977; 17:990–997.


45. Sande MA, Scheld M. Combination antibiotic therapy of bacterial endocarditis. Ann Intern Med. 1980;
    92:390–395.


46. Shelburne SA, Musher DM, Hulten K, et al. In vitro killing of community-associated methicillin-
    resistantStaphylococcus aureuswith drug combinations. Antimicrob Agent Chemother 2004; 48:
    4016–4019.


47. Lee DG, Chun HS, Yim DS, et al. Efficacies of vancomycin, arbekacin, and gentamicin alone or in
    combination against methicillin-resistantStaphylococcus aureusin an in vitro infective endocarditis
    model. Antimicrob Agents Chemother 2003; 47:3768–3773.


48. Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in
    methicillin-resistantStaphylococcus aureusendocarditis. Ann Intern Med 1991; 115:674–680.


49. Geraci JE, Wilson WR. Vancomycin therapy for infective endocarditis. Rev Infect Dis 1981; 3(suppl):
    S520–S258.


50. Hackbarth CJ, Chamberg HF, Sande MA. Serum bactericial acitivity of rifampin in combination
    with other antimicrobial agents againstStaphylococcus aureus.Antimicrob Agents Chemother 1986; 29:
    611–613.


51. Chang FY, Peacock JE Jr, Musher DM, et al.Staphylococcus aureusbacteremia: recurrence and the impact
    of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore) 2003; 82:333–339.


52. Cosgrove SE, Carroll KC, Perl TM.Staphylococcus aureuswith reduced susceptibility to vancomycin.
    Clin Infect Dis 2004; 39:539–545.

216 Cunha